Sotyktu FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 27, 2022.
FDA Approved: Yes (First approved September 9, 2022)
Brand name: Sotyktu
Generic name: deucravacitinib
Dosage form: Tablets
Company: Bristol-Myers Squibb Company
Treatment for: Plaque Psoriasis
Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- Sotyktu works to treat psoriasis by inhibiting TYK2, an intracellular signaling kinase that mediates signaling of IL-23, IL-12 and Type I IFN, which are naturally occurring cytokines involved in inflammatory and immune responses.
- Sotyktu is administered orally once daily, with or without food.
- Warnings and precautions associated with Sotyktu include hypersensitivity reactions, increased risk of infections, increased risk of developing malignancies including lymphomas; increased risk of developing rhabdomyolysis, and laboratory abnormalities.
- Common adverse reactions include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, and acne.
Development timeline for Sotyktu
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
